Entero Therapeutics (NASDAQ:ENTO) Releases Earnings Results

Entero Therapeutics (NASDAQ:ENTO) issued its earnings results on Wednesday. The company reported ($0.75) earnings per share (EPS) for the quarter, FiscalAI reports.

Entero Therapeutics Stock Performance

NASDAQ:ENTO opened at $3.08 on Thursday. Entero Therapeutics has a 52 week low of $0.97 and a 52 week high of $5.84. The firm’s 50-day simple moving average is $4.30 and its 200 day simple moving average is $2.51. The firm has a market cap of $4.89 million, a price-to-earnings ratio of -1.30 and a beta of 1.19.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Entero Therapeutics stock. Virtu Financial LLC purchased a new stake in Entero Therapeutics, Inc. (NASDAQ:ENTO) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 11,829 shares of the company’s stock, valued at approximately $59,000. Virtu Financial LLC owned approximately 0.74% of Entero Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 12.30% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on ENTO. Wall Street Zen upgraded shares of Entero Therapeutics to a “hold” rating in a report on Friday, October 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Entero Therapeutics in a research note on Tuesday, October 14th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Entero Therapeutics presently has an average rating of “Sell”.

Entero Therapeutics Company Profile

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.